Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Has the Anemia And Other Blood Disorder Drugs Market Growth Performance Trended Historically, And What Lies Ahead?

The market size for drugs treating anemia and various other blood disorders has shown significant growth in the recent past. There will be an increase from $11.61 billion in 2024 to $12.38 billion in 2025, reflecting a compound annual growth rate (CAGR) of 6.6%. Factors contributing to the growth during the historic period include disease prevalence, worldwide health initiatives, an increasing elderly population, innovation in the pharmaceutical sector, and heightened patient awareness.

What Is the Forecast for the Anemia And Other Blood Disorder Drugs Market Size Through 2029?

The market of drugs for anemia and other blood disorders is anticipated to witness robust growth in the upcoming years. The market is projected to expand to $16.09 billion by 2029, with a compound annual growth rate (CAGR) of 6.8%. The growth in the forecasted period can be ascribed to the emergence of new markets, global demographic changes, and economic factors. The major trends expected to shape the forecast period encompass research and development, technological progression, biologics and targeted therapies, gene therapies, telemedicine and remote monitoring, orphan drug designations, as well as mergers and acquisitions.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2465&type=smp

What are the Key Market Players in Anemia And Other Blood Disorder Drugs Market and How They’re Evolving?

Major companies operating in the anemia and other blood disorder drugs market include Amgen Inc, GlaxoSmithKline plc, Akebia Therapeutics Inc., Bayer AG, Pfizer Inc, F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme Corp., Novartis AG, Global Blood Therapeutics Inc., GlycoMimetics Inc., Eli Lilly and Company, FibroGen Inc., bluebird bio Inc., Acceleron Pharma Inc., AMAG Pharmaceuticals Inc., Pieris Pharmaceuticals Inc., Vifor Pharma Management Ltd., Sanofi S.A., Allergan U.S. Inc., Meda Consumer Healthcare Inc., AbbVie Inc., Johnson & Johnson, Daiichi Sankyo Company Limited, Galenica Ltd., Pharmacosmos A/S, Emmaus Medical Inc., Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Merck & Co. Inc., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., uniQure N.V., Rubius Therapeutics Inc., BioMarin Pharmaceutical Inc., Grifols S.A., Orchard Therapeutics plc

What Are the Primary Growth Drivers in the Anemia And Other Blood Disorder Drugs Market?

The escalating incidence of anemia in populations across the world propels the market forward. Poor health practices, modifications in food preferences, and heightened stress levels have all contributed to more instances of anemia worldwide. For example, anemia is the most common ailment in individuals over the age of 65, with a prevalence rate of approximately 17%. The World Bank has identified anemia as the eighth most frequent illness amongst women and young people. The increasing prevalence rate of anemia is stimulating growth in the anemia and other blood disorder drugs market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=2465&type=smp

What Are the Leading Segments in the Global Anemia And Other Blood Disorder Drugs Industry?

The anemia and other blood disorder drugs market covered in this report is segmented –

1) By Type: Iron Deficiency Anemia, Chronic Kidney Disease Anemia, Sickle Cell Anemia, Aplastic Anemia

2) By Route of Administration: Oral, Injectable

3) By Distribution Channel: Hospitals Pharmacy, Online Pharmacy, Pharmacy

Subsegments:

1) By Iron Deficiency Anemia: Oral Iron Supplements, Injectable Iron Supplements, Iron Fortified Foods

2) By Chronic Kidney Disease Anemia: Erythropoiesis-Stimulating Agents (ESAs), Iron Supplements, Blood Transfusion

3) By Sickle Cell Anemia: Hydroxyurea, Blood Transfusions, Gene Therapy, Pain Management Drugs

4) By Aplastic Anemia: Immunosuppressive Therapy, Stem Cell Transplantation, Erythropoiesis-Stimulating Agents (ESAs)

What Are the Key Market Trends in the Anemia And Other Blood Disorder Drugs Industry?

Companies operating within the anemia and other blood disorder pharmaceutical market are forming partnerships with government bodies. The aim is to jointly develop and launch specific drugs, sharing not just knowledge and technology, but also the financial burden. These partnerships can prove advantageous to corporations in light of licenses nearing their expiration and a strict regulatory landscape. Illustratively, Disc Medicine publicized their collaboration with the National Institutes of Health (NIH) and the National Heart, Lung, and Blood Institute (NHLBI) in March 2023. The partnership involves Phase 1/2 and Phase 2 clinical trials of biopterin in patients with Diamond-Blackfan Anemia (DBA) to cater to adult patients plagued by iron deficiency anemia. These studies will be conducted and financed by the NIH, in line with a cooperative research and development agreement (CRADA).

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

What Is the Regional Outlook for the Anemia And Other Blood Disorder Drugs Market?

North America was the largest region in the anemia and other blood disorder drugs market in 2023. Middle East is expected to be the fastest-growing region in the anemia and other blood disorder drugs market during the forecast period. The regions covered in the anemia and other blood disorder drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2465

This Report Delivers Insight On:

1. How big is the anemia and other blood disorder drugs market, and how is it changing globally?

2. Who are the major companies in the anemia and other blood disorder drugs market, and how are they performing?

3. What are the key opportunities and risks in the anemia and other blood disorder drugs market right now?

4. Which products or customer segments are growing the most in the anemia and other blood disorder drugs market?

5. What factors are helping or slowing down the growth of the anemia and other blood disorder drugs market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model